Bispo JAB, Pinheiro PS, Kobetz EK. Epidemiology and etiology of leukemia and lymphoma. Perspect Med 2020;10:a034819. DOI: https://doi.org/10.1101/cshperspect.a034819

Reksodiputro AH. Epidemiology study and mutation profile of patients with chronic myeloid leukemia (CML) in Indonesia. J Blood Disord Transfus 2015;06:1-13. DOI: https://doi.org/10.4172/2155-9864.1000271

Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol 2018;93:442-59. DOI: https://doi.org/10.1002/ajh.25011

Jabbour E. Chronic myeloid leukemia: first-line drug of choice. Am J Hematol 2016;91:59-66. DOI: https://doi.org/10.1002/ajh.24249

Zacchia M, Abategiovanni ML, Stratigis S, et al. Potassium: from physiology to clinical implications. Kidney Dis 2016;2:72-9. DOI: https://doi.org/10.1159/000446268

Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34:966-84. DOI: https://doi.org/10.1038/s41375-020-0776-2

Efficace F, Cannella L. The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematology 2016;2016:170-9. DOI: https://doi.org/10.1182/asheducation-2016.1.170

Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9. DOI: https://doi.org/10.1056/NEJMoa0912614

Shin J, Koh Y, Yoon SH, et al. A phase 4 study of nilotinib in Korean patients with philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea. Cancer Med 2018;7:1814-23. DOI: https://doi.org/10.1002/cam4.1450

Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016;30:1044-54. DOI: https://doi.org/10.1038/leu.2016.5

Steegmann JL, Baccarani M, Breccia M, et al. Recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016;30:1648-71. DOI: https://doi.org/10.1038/leu.2016.104

Yilmaz M, Lahoti A, O’Brien S, et al. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 2015;121:3894-904. DOI: https://doi.org/10.1002/cncr.29587

Marcolino MS, Boersma E, Clementino NCD, et al. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol 2011;22:2073-9. DOI: https://doi.org/10.1093/annonc/mdq715

Chuah CT, Nakamae H, Shen ZX, et al. Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase. Leuk Lymphoma 2014;55:2093-100. DOI: https://doi.org/10.3109/10428194.2013.866663

Wang J, Shen Z, Saglio G, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase : ENESTchina. Blood. 2015;125:2771-8. DOI: https://doi.org/10.1182/blood-2014-09-601674

Hasan BF, Matti BF, Hameed RY. Evaluation of electrolytes disturbances in Iraqi chronic myeloid leukemia patients treated with nilotinib with monitoring of response by FISH study. Baghdad Sci J 2015;12:110-8. DOI: https://doi.org/10.21123/bsj.12.1.110-118

Hochhaus A, Rosti G, Cross NCP, et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia 2016;30:57-64. DOI: https://doi.org/10.1038/leu.2015.270

Emadi E, Abdoli N, Ghanbarinejad V, et al. The potential role of mitochondrial impairment in the pathogenesis of imatinib-induced renal injury. Heliyon 2019;5:e01996. DOI: https://doi.org/10.1016/j.heliyon.2019.e01996

Udensi U, Tchounwou P. Potassium homeostasis, oxidative stress, and human disease. Int J Clin Exp Physiol 2017;4:111-22. DOI: https://doi.org/10.4103/ijcep.ijcep_43_17

Iyoda M, Shibata T, Hirai Y, et al. Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease. J Am Soc Nephrol 2011;22:1486-96. DOI: https://doi.org/10.1681/ASN.2010111158

Kardalas E, Paschou SA, Anagnostis P, et al. Hypokalemia: a clinical update. Endocr Connect 2018;7:R135-46. DOI: https://doi.org/10.1530/EC-18-0109

Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006-13. DOI: https://doi.org/10.1056/NEJMoa051140

Matti BF, Sabir F, Ali M, et al. Serum calcium and phosphate levels in patients with chronic myeloid leukemia taking different dose of tyrosine kinase inhibitors. Al-Mustansiriyah J Pharm Sci 2017;17:213-21.

O’Sullivan S, Horne A, Wattie D, et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 2009;94:1131-6. DOI: https://doi.org/10.1210/jc.2008-2324

O’Sullivan S, Lin JM, Watson M, et al. The skeletal effects of the tyrosine kinase inhibitor nilotinib. Bone 2011;49:281-9. DOI: https://doi.org/10.1016/j.bone.2011.04.014

Fong J. Clinical review: hypocalcemia. Can Fam Physician 2012;58:158–62.

Cortes JE, Lipton JH, Miller CB, et al. Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: The ENRICH study. Clin Lymphoma Myeloma Leuk 2016;16:286–96. DOI: https://doi.org/10.1016/j.clml.2016.02.002